Human infection with highly pathogenic H5N1 influenza virus

[1]  J. Moore,et al.  Avian influenza, migratory birds and emerging zoonoses: Unusual viral RNA, enteropathogens and Cryptosporidium in poultry litter , 2009, Bioscience Hypotheses.

[2]  C. C. Huang,et al.  Baculovirus-derived hemagglutinin vaccine protects chickens from lethal homologous virus H5N1 challenge. , 2008, The Journal of veterinary medical science.

[3]  T. Tumpey,et al.  Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle , 2008, PloS one.

[4]  A. Kumar,et al.  Three Indonesian Clusters of H5N1 Virus Infection in 2005 , 2008 .

[5]  Jiang Gu,et al.  H5N1 infection of the respiratory tract and beyond: a molecular pathology study , 2007, The Lancet.

[6]  J. Peiris,et al.  Influenza A/H5N1 virus infection in humans in Cambodia. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  K. Ungchusak,et al.  Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans , 2007, Emerging Infectious Diseases.

[8]  R. Webster,et al.  Efficacy of Oseltamivir Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus , 2007, Antimicrobial Agents and Chemotherapy.

[9]  Keiji Fukuda,et al.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.

[10]  R. Webster,et al.  Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice , 2006, Antiviral therapy.

[11]  A. Oner,et al.  Avian influenza A (H5N1) infection in eastern Turkey in 2006. , 2006, The New England journal of medicine.

[12]  Yi Guan,et al.  Three Indonesian clusters of H5N1 virus infection in 2005. , 2006, The New England journal of medicine.

[13]  Philippe Buchy,et al.  Low Frequency of Poultry-to-Human H5N1 Transmission, Southern Cambodia, 2005 , 2006, Emerging infectious diseases.

[14]  Yu Wang,et al.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial , 2006, The Lancet.

[15]  Yi Guan,et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.

[16]  Y. Lau,et al.  Differential Expression of Chemokines and Their Receptors in Adult and Neonatal Macrophages Infected with Human or Avian Influenza Viruses , 2006, The Journal of infectious diseases.

[17]  R. Webster,et al.  Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. , 2006, Antiviral research.

[18]  Y. Kawaoka,et al.  Properties and Dissemination of H5N1 Viruses Isolated during an Influenza Outbreak in Migratory Waterfowl in Western China , 2006, Journal of Virology.

[19]  P. Bhattarakosol,et al.  H5N1 Influenza A Virus and Infected Human Plasma , 2006, Emerging infectious diseases.

[20]  E. Mundt,et al.  Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. García-Sastre,et al.  Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Buchan,et al.  The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. , 2006, Vaccine.

[23]  J. Haynes,et al.  Epidermal DNA vaccine for influenza is immunogenic in humans. , 2006, Vaccine.

[24]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[25]  R. Couch,et al.  Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. , 2006, The Journal of infectious diseases.

[26]  Ian A. Wilson,et al.  Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus , 2006, Science.

[27]  Derek J Smith,et al.  Predictability and Preparedness in Influenza Control , 2006, Science.

[28]  Thijs Kuiken,et al.  H5N1 Virus Attachment to Lower Respiratory Tract , 2006, Science.

[29]  J. Peiris,et al.  Functional Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Production by Avian Influenza Virus–Infected Macrophages , 2006, The Journal of infectious diseases.

[30]  A. Amonsin,et al.  Avian Influenza H5N1 in Naturally Infected Domestic Cat , 2006, Emerging infectious diseases.

[31]  Yoshihiro Kawaoka,et al.  Avian flu: Influenza virus receptors in the human airway , 2006, Nature.

[32]  Y. Guan,et al.  Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Wentao Gao,et al.  Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization , 2006, Journal of Virology.

[34]  J. Katz,et al.  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice , 2006, The Lancet.

[35]  Weizhong Yang,et al.  The first confirmed human case of avian influenza A (H5N1) in Mainland China , 2006, The Lancet.

[36]  P. Doherty,et al.  Cell-mediated Protection in Influenza Infection , 2006, Emerging infectious diseases.

[37]  M. Osterholm,et al.  Preparing for the next pandemic. , 2005, The New England journal of medicine.

[38]  T. Uyeki,et al.  Low Frequency of Poultry-to-Human H 5 N 1 Virus Transmission , Southern Cambodia , 2005 , 2006 .

[39]  J. Stockman.  Probable Person-to-Person Transmission of Avian Influenza A (H5N1) , 2006 .

[40]  T. Kuiken,et al.  Immunopathology and Infectious Diseases Influenza A Virus ( H 5 N 1 ) Infection in Cats Causes Systemic Disease with Potential Novel Routes of Virus Spread within and between Hosts , 2005 .

[41]  B. Murphy,et al.  Development of effective vaccines against pandemic influenza. , 2006, Immunity.

[42]  Kridsada Chaichoune,et al.  The effect of temperature and UV light on infectivity of avian influenza virus (H5N1, Thai field strain) in chicken fecal manure. , 2006, The Southeast Asian journal of tropical medicine and public health.

[43]  C. Macken,et al.  Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses , 2005, Antiviral therapy.

[44]  T. Tumpey,et al.  Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. , 2005, Vaccine.

[45]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[46]  G. Nabel,et al.  Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. , 2005, Vaccine.

[47]  Y. Guan,et al.  Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells , 2005, Respiratory research.

[48]  M. St. Claire,et al.  Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates , 2005, Journal of Virology.

[49]  Timothy M. Uyeki,et al.  Family Clustering of Avian Influenza A (H5N1) , 2005, Emerging infectious diseases.

[50]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[51]  Angus Nicoll,et al.  Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.

[52]  N. Cox,et al.  Avian Influenza (H5N1) Viruses Isolated from Humans in Asia in 2004 Exhibit Increased Virulence in Mammals , 2005, Journal of Virology.

[53]  G. Gao,et al.  Highly Pathogenic H5N1 Influenza Virus Infection in Migratory Birds , 2005, Science.

[54]  A. H. Law,et al.  p38 Mitogen-Activated Protein Kinase-Dependent Hyperinduction of Tumor Necrosis Factor Alpha Expression in Response to Avian Influenza Virus H5N1 , 2005, Journal of Virology.

[55]  R. Webster,et al.  Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. , 2005, The Journal of infectious diseases.

[56]  Y. Guan,et al.  Avian flu: H5N1 virus outbreak in migratory waterfowl , 2005, Nature.

[57]  J. Farrar,et al.  Avian Influenza H5N1 and Healthcare Workers , 2005, Emerging infectious diseases.

[58]  J. Nicholls,et al.  Influenza A H5N1 Replication Sites in Humans , 2005, Emerging infectious diseases.

[59]  R. Bugarini,et al.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. , 2005, The Journal of infectious diseases.

[60]  D. Swayne,et al.  Experimental Study to Determine if Low-Pathogenicity and High-Pathogenicity Avian Influenza Viruses Can Be Present in Chicken Breast and Thigh Meat Following Intranasal Virus Inoculation , 2005, Avian diseases.

[61]  J. Farrar,et al.  Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. , 2005, The New England journal of medicine.

[62]  Yi Guan,et al.  Lethality to Ferrets of H5N1 Influenza Viruses Isolated from Humans and Poultry in 2004 , 2005, Journal of Virology.

[63]  Prasert Auewarakul,et al.  Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. , 2005, The Journal of general virology.

[64]  N. Liem,et al.  Lack of H5N1 Avian Influenza Transmission to Hospital Employees, Hanoi, 2004 , 2005, Emerging infectious diseases.

[65]  S. Dowell,et al.  Human Disease from Influenza A (H5N1), Thailand, 2004 , 2005, Emerging infectious diseases.

[66]  Prasert Auewarakul,et al.  Probable person-to-person transmission of avian influenza A (H5N1). , 2005, The New England journal of medicine.

[67]  C. Elmets,et al.  Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. , 2005, Vaccine.

[68]  M. Peiris,et al.  Clinical Features and Rapid Viral Diagnosis of Human Disease Associated with Avian Influenza a H5n1 Virus and Members of the H5n1 Study Group* , 2022 .

[69]  Yong Poovorawan,et al.  Avian Influenza H5N1 in Tigers and Leopards , 2004, Emerging infectious diseases.

[70]  T. Uyeki,et al.  Neurologic Complications Associated With Influenza A in Children During the 2003–2004 Influenza Season in Houston, Texas , 2004, Pediatrics.

[71]  Thijs Kuiken,et al.  Avian H5N1 Influenza in Cats , 2004, Science.

[72]  M. Tang,et al.  Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. , 2004, Vaccine.

[73]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[74]  A. Charlett,et al.  Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. , 2004, Virus research.

[75]  R. Webster,et al.  The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. , 2004, Virus research.

[76]  A. Apisarnthanarak,et al.  Atypical Avian Influenza (H5N1) , 2004, Emerging infectious diseases.

[77]  C. Fraser,et al.  Public Health Risk from the Avian H5N1 Influenza Epidemic , 2004, Science.

[78]  Y. Guan,et al.  Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines , 2004, The Lancet.

[79]  H. Whittle,et al.  Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States , 2004, Clinical Diagnostic Laboratory Immunology.

[80]  J. Peiris,et al.  Re-emergence of fatal human influenza A subtype H5N1 disease , 2004, The Lancet.

[81]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[82]  J. Shiver,et al.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. , 2004, Annual review of medicine.

[83]  R. Cox,et al.  Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.

[84]  John Bartlett,et al.  Avian influenza A (H5N1) in 10 patients in Vietnam , 2004 .

[85]  K. Yuen,et al.  Peiris, J.S.M. et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363, 617−619 , 2004 .

[86]  T. Kuiken,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[87]  R. Compans,et al.  Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus Conjugated with Cholera Toxin Subunit B , 2003, Journal of Virology.

[88]  Y. Kawaoka,et al.  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. , 2003, Vaccine.

[89]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[90]  Y. Guan,et al.  Neurovirulence in Mice of H5N1 Influenza Virus Genotypes Isolated from Hong Kong Poultry in 2001 , 2003, Journal of Virology.

[91]  T. Francis,et al.  CHARACTERIZATION OF INFLUENZA ANTIBODIES BY SERUM , 2003 .

[92]  Thorsten Lang,et al.  Membrane fusion. , 2002, Current opinion in cell biology.

[93]  Y. Guan,et al.  Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.

[94]  Michael G. Katze,et al.  Viruses and interferon: a fight for supremacy , 2002, Nature Reviews Immunology.

[95]  M. Tashiro,et al.  Encephalitis and encephalopathy associated with an influenza epidemic in Japan. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  R. Webster,et al.  Lethal H5N1 influenza viruses escape host anti-viral cytokine responses , 2002, Nature Medicine.

[97]  Roger E Bumgarner,et al.  Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[98]  H. Klenk,et al.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.

[99]  C. Bridges,et al.  Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. , 2002, The Journal of infectious diseases.

[100]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[101]  J. Wood.  Developing vaccines against pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[102]  H. Goto,et al.  Plasminogen-Binding Activity of Neuraminidase Determines the Pathogenicity of Influenza A Virus , 2001, Journal of Virology.

[103]  R. Webster,et al.  Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.

[104]  Yoshihiro Kawaoka,et al.  Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses , 2001, Science.

[105]  J. Galarza,et al.  Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins , 2001, Journal of Virology.

[106]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[107]  R. Webster,et al.  Efficacy of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in Mammals , 2001, Antimicrobial Agents and Chemotherapy.

[108]  R. Sung,et al.  Pathology of fatal human infection associated with avian influenza A H5N1 virus , 2001, Journal of medical virology.

[109]  W. Blackwelder,et al.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. , 2001, Vaccine.

[110]  A. García-Sastre,et al.  Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. , 2001, Virology.

[111]  Yoshihiro Kawaoka,et al.  Pandemic Threat Posed by Avian Influenza A Viruses , 2001, Clinical Microbiology Reviews.

[112]  P. Doherty,et al.  Profound Protection against Respiratory Challenge with a Lethal H7N7 Influenza A Virus by Increasing the Magnitude of CD8+ T-Cell Memory , 2000, Journal of Virology.

[113]  R. Webster,et al.  Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. , 2000, The Journal of general virology.

[114]  R. Webster,et al.  The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.

[115]  Yoshihiro Kawaoka,et al.  Early Alterations of the Receptor-Binding Properties of H1, H2, and H3 Avian Influenza Virus Hemagglutinins after Their Introduction into Mammals , 2000, Journal of Virology.

[116]  M. Shaw,et al.  Molecular aspects of avian influenza (H5N1) viruses isolated from humans , 2000, Reviews in medical virology.

[117]  T. Tumpey,et al.  Depletion of Lymphocytes and Diminished Cytokine Production in Mice Infected with a Highly Virulent Influenza A (H5N1) Virus Isolated from Humans , 2000, Journal of Virology.

[118]  L. Mitnaul,et al.  Balanced Hemagglutinin and Neuraminidase Activities Are Critical for Efficient Replication of Influenza A Virus , 2000, Journal of Virology.

[119]  Y. Kawaoka,et al.  Host-range barrier of influenza A viruses. , 2000, Veterinary microbiology.

[120]  P. Fast,et al.  Genotypic Stability of Cold-Adapted Influenza Virus Vaccine in an Efficacy Clinical Trial , 2000, Journal of Clinical Microbiology.

[121]  William Ho,et al.  Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. , 2000, The Journal of infectious diseases.

[122]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[123]  C. Bridges,et al.  Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. , 1999, The Journal of infectious diseases.

[124]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[125]  C. Bridges,et al.  Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. , 1999, The Journal of infectious diseases.

[126]  Maricarmen García,et al.  Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. , 1999, Vaccine.

[127]  K. Subbarao,et al.  Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. , 1999, The Journal of infectious diseases.

[128]  H. Goto,et al.  Biological Heterogeneity, Including Systemic Replication in Mice, of H5N1 Influenza A Virus Isolates from Humans in Hong Kong , 1999, Journal of Virology.

[129]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[130]  R. Webster,et al.  DNA Vaccine Encoding Hemagglutinin Provides Protective Immunity against H5N1 Influenza Virus Infection in Mice , 1999, Journal of Virology.

[131]  D. Levy,et al.  Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. , 1998, Virology.

[132]  R. Webster,et al.  Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. , 1998, The Journal of infectious diseases.

[133]  A. García-Sastre,et al.  The Role of Interferon in Influenza Virus Tissue Tropism , 1998, Journal of Virology.

[134]  S. Fujimoto,et al.  PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis , 1998, The Lancet.

[135]  H. Goto,et al.  A novel mechanism for the acquisition of virulence by a human influenza A virus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[136]  F. Hayden,et al.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.

[137]  A. Osterhaus,et al.  Human influenza virus A/HongKong/156/97 (H5N1) infection. , 1998, Vaccine.

[138]  M. Peiris,et al.  Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus , 1998, The Lancet.

[139]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[140]  K. Nakajima.  [Neurovirulence of influenza virus in mice]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[141]  R. Webster,et al.  Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin , 1997, Journal of virology.

[142]  J. Shiver,et al.  DNA vaccines. , 1997, Annual review of immunology.

[143]  R. Betts,et al.  Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. , 1996, The Journal of infectious diseases.

[144]  R. Betts,et al.  Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. , 1996, The Journal of infectious diseases.

[145]  J. Shiver,et al.  Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus , 1995, Nature Medicine.

[146]  R. Webster,et al.  Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. , 1994, Vaccine.

[147]  J. Ulmer,et al.  Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. , 1994, Vaccine.

[148]  R. Webster,et al.  Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. , 1994, Virology.

[149]  P. Palese,et al.  Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus , 1993, Journal of virology.

[150]  J. Paulson,et al.  Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. , 1993, Virus research.

[151]  B. Murphy,et al.  A single amino acid in the PB2 gene of influenza A virus is a determinant of host range , 1993, Journal of virology.

[152]  Y. Kawaoka,et al.  Biologic importance of neuraminidase stalk length in influenza A virus , 1993, Journal of virology.

[153]  P. Palese,et al.  Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. , 1993, Virus research.

[154]  R. Webster,et al.  Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. , 1993, Vaccine.

[155]  R. Karron,et al.  Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers , 1992, Journal of clinical microbiology.

[156]  J. Skehel,et al.  Deacylation of the hemagglutinin of influenza A/Aichi/2/68 has no effect on membrane fusion properties. , 1991, Virology.

[157]  J. Paulson,et al.  Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. , 1990, Acta histochemica. Supplementband.

[158]  G. N. Rogers,et al.  Receptor binding properties of human and animal H1 influenza virus isolates. , 1989, Virology.

[159]  H. Klenk,et al.  The Molecular Biology of Influenza Virus Pathogenicity , 1988, Advances in Virus Research.

[160]  R. Webster,et al.  Influenza virus a pathogenicity: The pivotal role of hemagglutinin , 1987, Cell.

[161]  C. Naeve,et al.  Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus , 1984, Journal of virology.

[162]  J. Paulson,et al.  Differential sensitivity of human, avian, and equine influenza A viruses to a glycoprotein inhibitor of infection: selection of receptor specific variants. , 1983, Virology.

[163]  I. Wilson,et al.  Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity , 1983, Nature.

[164]  J. Paulson,et al.  Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. , 1983, Virology.

[165]  I. Kharitonenkov,et al.  [Proteolytic cleavage of influenza virus matrix protein and nucleoprotein in an in vitro system]. , 1983, Voprosy virusologii.

[166]  H. Klenk,et al.  Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. , 1981, Virology.

[167]  M. Ueda,et al.  Neurovirulence of influenza virus in mice. I. Neurovirulence of recombinants between virulent and avirulent virus strains. , 1980, Virology.

[168]  S. Nakajima,et al.  Neurovirulence of influenza virus in mice. II. Mechanism of virulence as studied in a neuroblastoma cell line. , 1980, Virology.

[169]  H. Klenk,et al.  The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. , 1979, Virology.

[170]  J. Almond,et al.  A single gene determines the host range of influenza virus , 1977, Nature.

[171]  W. Vaughn,et al.  Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. , 1977, The Journal of infectious diseases.

[172]  P. Palese,et al.  Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells , 1977, Journal of virology.

[173]  H. Klenk,et al.  Activation of influenza A viruses by trypsin treatment. , 1975, Virology.

[174]  P. Choppin,et al.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. , 1975, Virology.

[175]  R. Compans,et al.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.

[176]  F. Murphy,et al.  Immunization against Viral Diseases , 1968 .

[177]  T. Tumpey,et al.  Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle , 2008, PloS one.

[178]  R. Webster,et al.  Efficacy of Oseltamivir Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus , 2007, Antimicrobial Agents and Chemotherapy.

[179]  R. Webster,et al.  Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice , 2006, Antiviral therapy.

[180]  Y. Lau,et al.  Differential Expression of Chemokines and Their Receptors in Adult and Neonatal Macrophages Infected with Human or Avian Influenza Viruses , 2006, The Journal of infectious diseases.

[181]  R. Webster,et al.  Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. , 2006, Antiviral research.

[182]  Y. Kawaoka,et al.  Properties and Dissemination of H5N1 Viruses Isolated during an Influenza Outbreak in Migratory Waterfowl in Western China , 2006, Journal of Virology.

[183]  P. Bhattarakosol,et al.  H5N1 Influenza A Virus and Infected Human Plasma , 2006, Emerging infectious diseases.

[184]  A. García-Sastre,et al.  Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[185]  G. Buchan,et al.  The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. , 2006, Vaccine.

[186]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[187]  R. Couch,et al.  Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. , 2006, The Journal of infectious diseases.

[188]  Ian A. Wilson,et al.  Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus , 2006, Science.

[189]  Thijs Kuiken,et al.  H5N1 Virus Attachment to Lower Respiratory Tract , 2006, Science.

[190]  J. Peiris,et al.  Functional Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Production by Avian Influenza Virus–Infected Macrophages , 2006, The Journal of infectious diseases.

[191]  Yoshihiro Kawaoka,et al.  Avian flu: Influenza virus receptors in the human airway , 2006, Nature.

[192]  J. Katz,et al.  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice , 2006, The Lancet.

[193]  P. Doherty,et al.  Cell-mediated Protection in Influenza Infection , 2006, Emerging infectious diseases.

[194]  C. Macken,et al.  Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses , 2005, Antiviral therapy.

[195]  T. Tumpey,et al.  Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. , 2005, Vaccine.

[196]  M. St. Claire,et al.  Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates , 2005, Journal of Virology.

[197]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[198]  N. Cox,et al.  Avian Influenza (H5N1) Viruses Isolated from Humans in Asia in 2004 Exhibit Increased Virulence in Mammals , 2005, Journal of Virology.

[199]  G. Gao,et al.  Highly Pathogenic H5N1 Influenza Virus Infection in Migratory Birds , 2005, Science.

[200]  R. Webster,et al.  Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. , 2005, The Journal of infectious diseases.

[201]  Y. Guan,et al.  Avian flu: H5N1 virus outbreak in migratory waterfowl , 2005, Nature.

[202]  Yi Guan,et al.  Lethality to Ferrets of H5N1 Influenza Viruses Isolated from Humans and Poultry in 2004 , 2005, Journal of Virology.

[203]  Prasert Auewarakul,et al.  Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. , 2005, The Journal of general virology.

[204]  C. Elmets,et al.  Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. , 2005, Vaccine.

[205]  T. Uyeki,et al.  Neurologic Complications Associated With Influenza A in Children During the 2003–2004 Influenza Season in Houston, Texas , 2004, Pediatrics.

[206]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[207]  A. Charlett,et al.  Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. , 2004, Virus research.

[208]  Y. Guan,et al.  Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines , 2004, The Lancet.

[209]  H. Whittle,et al.  Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States , 2004, Clinical Diagnostic Laboratory Immunology.

[210]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[211]  R. Compans,et al.  Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus Conjugated with Cholera Toxin Subunit B , 2003, Journal of Virology.

[212]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[213]  Y. Guan,et al.  Neurovirulence in Mice of H5N1 Influenza Virus Genotypes Isolated from Hong Kong Poultry in 2001 , 2003, Journal of Virology.

[214]  Michael G. Katze,et al.  Viruses and interferon: a fight for supremacy , 2002, Nature Reviews Immunology.

[215]  R. Webster,et al.  Lethal H5N1 influenza viruses escape host anti-viral cytokine responses , 2002, Nature Medicine.

[216]  H. Klenk,et al.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.

[217]  C. Bridges,et al.  Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. , 2002, The Journal of infectious diseases.

[218]  J. Galarza,et al.  Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins , 2001, Journal of Virology.

[219]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[220]  R. Webster,et al.  Efficacy of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in Mammals , 2001, Antimicrobial Agents and Chemotherapy.

[221]  R. Sung,et al.  Pathology of fatal human infection associated with avian influenza A H5N1 virus , 2001, Journal of medical virology.

[222]  W. Blackwelder,et al.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. , 2001, Vaccine.

[223]  A. García-Sastre,et al.  Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. , 2001, Virology.

[224]  Yoshihiro Kawaoka,et al.  Pandemic Threat Posed by Avian Influenza A Viruses , 2001, Clinical Microbiology Reviews.

[225]  P. Doherty,et al.  Profound Protection against Respiratory Challenge with a Lethal H7N7 Influenza A Virus by Increasing the Magnitude of CD8+ T-Cell Memory , 2000, Journal of Virology.

[226]  R. Webster,et al.  Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. , 2000, The Journal of general virology.

[227]  R. Webster,et al.  The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.

[228]  L. Mitnaul,et al.  Balanced Hemagglutinin and Neuraminidase Activities Are Critical for Efficient Replication of Influenza A Virus , 2000, Journal of Virology.

[229]  Y. Kawaoka,et al.  Host-range barrier of influenza A viruses. , 2000, Veterinary microbiology.

[230]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[231]  Maricarmen García,et al.  Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. , 1999, Vaccine.

[232]  H. Goto,et al.  Biological Heterogeneity, Including Systemic Replication in Mice, of H5N1 Influenza A Virus Isolates from Humans in Hong Kong , 1999, Journal of Virology.

[233]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[234]  R. Webster,et al.  DNA Vaccine Encoding Hemagglutinin Provides Protective Immunity against H5N1 Influenza Virus Infection in Mice , 1999, Journal of Virology.

[235]  D. Levy,et al.  Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. , 1998, Virology.

[236]  A. García-Sastre,et al.  The Role of Interferon in Influenza Virus Tissue Tropism , 1998, Journal of Virology.

[237]  H. Goto,et al.  A novel mechanism for the acquisition of virulence by a human influenza A virus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[238]  F. Hayden,et al.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.

[239]  A. Osterhaus,et al.  Human influenza virus A/HongKong/156/97 (H5N1) infection. , 1998, Vaccine.

[240]  R. Webster,et al.  Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin , 1997, Journal of virology.

[241]  R. Betts,et al.  Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. , 1996, The Journal of infectious diseases.

[242]  R. Betts,et al.  Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. , 1996, The Journal of infectious diseases.

[243]  J. Shiver,et al.  Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus , 1995, Nature Medicine.

[244]  R. Webster,et al.  Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. , 1994, Vaccine.

[245]  R. Webster,et al.  Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. , 1994, Virology.

[246]  J. Paulson,et al.  Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. , 1993, Virus research.

[247]  B. Murphy,et al.  A single amino acid in the PB2 gene of influenza A virus is a determinant of host range , 1993, Journal of virology.

[248]  Y. Kawaoka,et al.  Biologic importance of neuraminidase stalk length in influenza A virus , 1993, Journal of virology.

[249]  R. Webster,et al.  Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. , 1993, Vaccine.

[250]  R. Karron,et al.  Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers , 1992, Journal of clinical microbiology.

[251]  J. Paulson,et al.  Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. , 1990, Acta histochemica. Supplementband.

[252]  G. N. Rogers,et al.  Receptor binding properties of human and animal H1 influenza virus isolates. , 1989, Virology.

[253]  H. Klenk,et al.  The Molecular Biology of Influenza Virus Pathogenicity , 1988, Advances in Virus Research.

[254]  R. Webster,et al.  Influenza virus a pathogenicity: The pivotal role of hemagglutinin , 1987, Cell.

[255]  C. Naeve,et al.  Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus , 1984, Journal of virology.

[256]  J. Paulson,et al.  Differential sensitivity of human, avian, and equine influenza A viruses to a glycoprotein inhibitor of infection: selection of receptor specific variants. , 1983, Virology.

[257]  I. Wilson,et al.  Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity , 1983, Nature.

[258]  J. Paulson,et al.  Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. , 1983, Virology.

[259]  H. Klenk,et al.  Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. , 1981, Virology.

[260]  M. Ueda,et al.  Neurovirulence of influenza virus in mice. I. Neurovirulence of recombinants between virulent and avirulent virus strains. , 1980, Virology.

[261]  S. Nakajima,et al.  Neurovirulence of influenza virus in mice. II. Mechanism of virulence as studied in a neuroblastoma cell line. , 1980, Virology.

[262]  H. Klenk,et al.  The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. , 1979, Virology.

[263]  W. Vaughn,et al.  Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. , 1977, The Journal of infectious diseases.

[264]  P. Palese,et al.  Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells , 1977, Journal of virology.

[265]  P. Choppin,et al.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. , 1975, Virology.

[266]  R. Compans,et al.  Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.

[267]  F. Murphy,et al.  Immunization against Viral Diseases , 1968 .